IntroductionFenestrated endografts (FEVAR) have been a safe and effective solution in our institution for patients with juxta-renal abdominal aortic aneurysms that were not candidates for conventional repair and had suitable anatomy. The objective of our study was to evaluate the long-term outcomes of these interventions. MethodsBetween September 2005 and December 2021, this study included all the patients bearing juxta-renal aneurysm electively treated with a fenestrated endograft. We conducted a retrospective analysis of prospectively collected monocentric data. Preoperative, perioperative, and postoperative data were processed. Postoperative follow-up included at least a systematic computed tomography scan at 6, 12, 18 and 24 months then every year. Secondary procedure was defined as any additional procedure performed to treat aneurysm or endograft-related complications after index procedure. Demographic and perioperative data were analyzed descriptively. Overall survival and freedom from secondary procedures were determined using the Kaplan-Meier estimate. ResultsA total of 169 patients (92% male) were treated by fenestrated endograft with a mean 55 ± 37 months follow-up. The median aneurysm diameter was 59 mm. In 39 patients (23.1%), we performed a secondary procedure, by endovascular means in 57% of cases, mostly after the first year of follow-up (53.8%). The most frequent cause for secondary procedure was type 1b endoleak due to the evolution of aneurysmal disease of the iliac arteries (25.6%), followed by endograft limb thrombosis (20.5%), local complications related to index procedure (17.9%) and procedures performed to insure target vessel patency over time (18%). On the last CT scan of the follow-up, patients without secondary procedure were significantly more likely to present a shrinkage of the aneurysmal sac (p= 0.001), defined as a modification of the maximum diameter > 5mm. Overall survival was not significantly different between patients that had secondary procedures compared to those that had not (80 months vs 62 months, p=0.3). Freedom from secondary procedures was 87% at 24 months and 63% at 60 months. Excluding secondary procedures within 30 days, freedom from secondary procedures was 76% at 50 months. ConclusionFenestrated endografts constitute a sustainable therapeutic solution in the treatment of juxtarenal abdominal aortic aneurysms. The occurrence of late complications justifies a rigorous follow-up of treated patients.
Read full abstract